Dr. Stella Kang weighs in on prostate MRIs
“It is always important to think about how the imaging and the way we read the imaging can improve, right and be used in a way that makes the most sense for the decision at hand,” says Stella K. Kang, MD, in this podcast.
In this episode, Urology Times® Managing Editor Ben Saylor spoke with Dr. Stella K. Kang. She discusses the recent Radiology study titled, "Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness,” for which she served as a study author. Kang is an associate professor of radiology and population health and director of Comparative Effectiveness and Outcomes Research in the department of radiology at NYU Grossman School of Medicine, New York.
Dr. Agarwal on significance of ultra-low PSA levels achieved with apalutamide in mCSPC
January 11th 2024Neeraj Agarwal, MD, discusses an analysis from the phase 3 TITAN trial that explored the correlation between PSA response and survival among patients with metastatic castration-sensitive prostate cancer receiving apalutamide.
